메뉴 건너뛰기




Volumn 37, Issue 8, 2014, Pages 957-966

Clinical implication of SGLT2 inhibitors in type 2 diabetes

Author keywords

SGLT2 inhibitor; Sodium glucose co transporter 2 (SGLT2); Type 2 diabetes mellitus

Indexed keywords

1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CANAGLIFLOZIN; GLUCOSE; GLUCOSIDE; INSULIN; IPRAGLIFLOZIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL; THIOPHENE DERIVATIVE;

EID: 84926098474     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0419-0     Document Type: Review
Times cited : (17)

References (53)
  • 2
    • 77953857048 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial
    • 1:CAS:528:DC%2BC3cXotVagtro%3D
    • Bailey, C.J., J.L. Gross, A. Pieters, A. Bastien, and J.F. List. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
    • (2010) Lancet , vol.375 , pp. 2223-2233
    • Bailey, C.J.1    Gross, J.L.2    Pieters, A.3    Bastien, A.4    List, J.F.5
  • 4
    • 84880543926 scopus 로고
    • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
    • Bode, B., K. Stenlöf, D. Sullivan, A. Fung, and K. Usiskin. 1995. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hospital Practice 41: 72-84.
    • (1995) Hospital Practice , vol.41 , pp. 72-84
    • Bode, B.1    Stenlöf, K.2    Sullivan, D.3    Fung, A.4    Usiskin, K.5
  • 5
    • 84858020943 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
    • 1:CAS:528:DC%2BC38Xkt1yms78%3D
    • Bolinder, J., O. Ljunggren, J. Kullberg, L. Johansson, J. Wildding, A.M. Langkilde, J. Sugg, and S. Parikh. 2012. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. The Journal of Clinical Endoclinology & Metabolism 97: 1020-1031.
    • (2012) The Journal of Clinical Endoclinology & Metabolism , vol.97 , pp. 1020-1031
    • Bolinder, J.1    Ljunggren, O.2    Kullberg, J.3    Johansson, L.4    Wildding, J.5    Langkilde, A.M.6    Sugg, J.7    Parikh, S.8
  • 6
    • 47149095990 scopus 로고    scopus 로고
    • Pancreatic alphacell dysfunction in diabetes
    • 1:CAS:528:DC%2BD1cXnvVGgs7s%3D
    • Burcelin, R., C. Knauf, and P.D. Cani. 2008. Pancreatic alphacell dysfunction in diabetes. Diabetes Metabolism 34: S49-S55.
    • (2008) Diabetes Metabolism , vol.34 , pp. 49-S55
    • Burcelin, R.1    Knauf, C.2    Cani, P.D.3
  • 7
    • 0032952105 scopus 로고    scopus 로고
    • Insulin regulation of renal glucose metabolism in humans
    • 1:CAS:528:DyaK1MXntlaqug%3D%3D 9886953
    • Cersosimo, E., P. Garlick, and J. Ferretti. 1999. Insulin regulation of renal glucose metabolism in humans. American Journal of Physiology 276: E78-E84.
    • (1999) American Journal of Physiology , vol.276 , pp. 78-E84
    • Cersosimo, E.1    Garlick, P.2    Ferretti, J.3
  • 8
    • 77954242599 scopus 로고    scopus 로고
    • SGLT2 inhibition: A novel strategy for diabetes treatment
    • 1:CAS:528:DC%2BC3cXmsF2itLc%3D
    • Chao, E.C., and R.R. Henry. 2010. SGLT2 inhibition: A novel strategy for diabetes treatment. Nature Reviews Drug Discovery 9: 551-559.
    • (2010) Nature Reviews Drug Discovery , vol.9 , pp. 551-559
    • Chao, E.C.1    Henry, R.R.2
  • 9
    • 73249141243 scopus 로고    scopus 로고
    • 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation
    • Copper, M.S., and P.M. Stewart. 2009. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. The Journal of Clinical Endocrinology and Metabolism 94: 4645-4654.
    • (2009) The Journal of Clinical Endocrinology and Metabolism , vol.94 , pp. 4645-4654
    • Copper, M.S.1    Stewart, P.M.2
  • 10
    • 77956164758 scopus 로고    scopus 로고
    • American Diabetes Association: 70th scientific sessions: Research on novel therapeutics: Part 1
    • Croasdell, G. 2010. American Diabetes Association: 70th scientific sessions: Research on novel therapeutics: Part 1. The Investigational Dugs Journal 13: 595-597.
    • (2010) The Investigational Dugs Journal , vol.13 , pp. 595-597
    • Croasdell, G.1
  • 11
    • 0037034257 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    • Diabetes Prevention Program Research Group
    • Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 364: 393-403.
    • (2002) The New England Journal of Medicine , vol.364 , pp. 393-403
  • 12
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • 1:CAS:528:DC%2BD28XhtF2gurjM
    • Drucker, D.J., and M.A. Nauck. 2006. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 14
    • 63849342369 scopus 로고    scopus 로고
    • Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
    • 1:CAS:528:DC%2BD1MXltFejtbs%3D
    • Edgerton, D.S., K.M. Johnson, and A.D. Cherrington. 2009. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Frontiers in Bioscience 14: 1169-1181.
    • (2009) Frontiers in Bioscience , vol.14 , pp. 1169-1181
    • Edgerton, D.S.1    Johnson, K.M.2    Cherrington, A.D.3
  • 16
    • 84939917152 scopus 로고    scopus 로고
    • FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 Mg. Sponsor: Bristol-Myers Squibb
    • FDA
    • FDA. 2011. FDA briefing document. NDA 202293. Dapagliflozin tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting.
    • (2011) Advisory Committee Meeting
  • 17
    • 84898791440 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
    • 1:CAS:528:DC%2BC2cXmsFWrtL0%3D
    • Forst, T., R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger, and P. Stein. 2014. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, Obesity & Metabolism 16: 467-477.
    • (2014) Diabetes, Obesity & Metabolism , vol.16 , pp. 467-477
    • Forst, T.1    Guthrie, R.2    Goldenberg, R.3    Yee, J.4    Vijapurkar, U.5    Meininger, G.6    Stein, P.7
  • 18
    • 52649083832 scopus 로고    scopus 로고
    • Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
    • 1:CAS:528:DC%2BD1cXht1amsLfL
    • Fujimori, Y., K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji. 2008. Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. The Journal of Pharmacology and Experimental Therapeutics 327: 268-276.
    • (2008) The Journal of Pharmacology and Experimental Therapeutics , vol.327 , pp. 268-276
    • Fujimori, Y.1    Katsuno, K.2    Nakashima, I.3    Ishikawa-Takemura, Y.4    Fujikura, H.5    Isaji, M.6
  • 20
    • 3042661013 scopus 로고    scopus 로고
    • Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog
    • 1:CAS:528:DC%2BD2cXlt1eltb0%3D
    • Gustavson, S.M., et al. 2004. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 53: 933-941.
    • (2004) Metabolism , vol.53 , pp. 933-941
    • Gustavson, S.M.1
  • 21
    • 38049083706 scopus 로고    scopus 로고
    • Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice
    • 1:CAS:528:DC%2BD2sXhtlCqtLbN
    • Han, G.C., S.K. Ko, J.H. Sung, and S.H. Chung. 2007. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. Journal of Agricultural and Food Chemistry 55: 10641-10648.
    • (2007) Journal of Agricultural and Food Chemistry , vol.55 , pp. 10641-10648
    • Han, G.C.1    Ko, S.K.2    Sung, J.H.3    Chung, S.H.4
  • 22
    • 48249146624 scopus 로고    scopus 로고
    • Dapagliflozin: A selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    • 1:CAS:528:DC%2BD1cXnsF2isL4%3D
    • Han, S., D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, J.R. Wetterau, W.N. Washburn, and J.M. Whaley. 2008. Dapagliflozin: A selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729.
    • (2008) Diabetes , vol.57 , pp. 1723-1729
    • Han, S.1    Hagan, D.L.2    Taylor, J.R.3    Xin, L.4    Meng, W.5    Biller, S.A.6    Wetterau, J.R.7    Washburn, W.N.8    Whaley, J.M.9
  • 23
    • 0027948971 scopus 로고
    • Molecular physiology of sodium-glucose cotransporters
    • 1:CAS:528:DyaK2MXitFGnsLs%3D 7938229
    • Hediger, M.A., and D.B. Rhoads. 1994. Molecular physiology of sodium-glucose cotransporters. Physiological Reviews 74: 993-1026.
    • (1994) Physiological Reviews , vol.74 , pp. 993-1026
    • Hediger, M.A.1    Rhoads, D.B.2
  • 24
    • 0023567264 scopus 로고
    • Expression cloning and cDNA sequencing of the Na(+)/glucose co-transporter
    • 1:CAS:528:DyaL1cXhsVCnsbg%3D
    • Hediger, M.A., M.J. Coady, T.S. Ikeda, and E.M. Wright. 1987. Expression cloning and cDNA sequencing of the Na(+)/glucose co-transporter. Nature 330: 379-381.
    • (1987) Nature , vol.330 , pp. 379-381
    • Hediger, M.A.1    Coady, M.J.2    Ikeda, T.S.3    Wright, E.M.4
  • 25
    • 0031770812 scopus 로고    scopus 로고
    • Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety
    • 1:CAS:528:DyaK1cXntVSlt74%3D
    • Hongu, M., N. Funami, Y. Takahashi, K. Saito, K. Arakawa, M. Matsumoto, H. Yamakita, and K. Tsujihara. 1998a. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 1545-1555.
    • (1998) Chemical & Pharmaceutical Bulletin (Tokyo) , vol.46 , pp. 1545-1555
    • Hongu, M.1    Funami, N.2    Takahashi, Y.3    Saito, K.4    Arakawa, K.5    Matsumoto, M.6    Yamakita, H.7    Tsujihara, K.8
  • 26
    • 0031934860 scopus 로고    scopus 로고
    • Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4-dehydroxyphlorizin derivatives
    • 1:CAS:528:DyaK1cXnsFegsw%3D%3D
    • Hongu, M., T. Tanaka, N. Funami, K. Saito, K. Arakawa, M. Matsumoto, and K. Tsujihara. 1998b. Na(+)-glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4-dehydroxyphlorizin derivatives. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 22-33.
    • (1998) Chemical & Pharmaceutical Bulletin (Tokyo) , vol.46 , pp. 22-33
    • Hongu, M.1    Tanaka, T.2    Funami, N.3    Saito, K.4    Arakawa, K.5    Matsumoto, M.6    Tsujihara, K.7
  • 27
    • 77953801665 scopus 로고    scopus 로고
    • Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study
    • 1:CAS:528:DC%2BC3cXns1CgsL8%3D
    • Hussey, E.K., R.L. Dobbins, R.R. Stoltz, N.L. Stockman, R.L. O'Connor-Semmes, A. Kapur, S.C. Murray, D. Layko, and D.J. Nunez. 2010. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study. Journal of Clinical Pharmacology 50: 636-646.
    • (2010) Journal of Clinical Pharmacology , vol.50 , pp. 636-646
    • Hussey, E.K.1    Dobbins, R.L.2    Stoltz, R.R.3    Stockman, N.L.4    O'Connor-Semmes, R.L.5    Kapur, A.6    Murray, S.C.7    Layko, D.8    Nunez, D.J.9
  • 28
    • 33845881411 scopus 로고    scopus 로고
    • Mechanisms linking obesity to insulin resistance and type 2 diabetes
    • 1:CAS:528:DC%2BD28XhtlShtrzP
    • Kahn, S.E., R.L. Hull, and K.M. Ulzschneider. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
    • (2006) Nature , vol.444 , pp. 840-846
    • Kahn, S.E.1    Hull, R.L.2    Ulzschneider, K.M.3
  • 31
    • 67349275999 scopus 로고    scopus 로고
    • Dapagliflozin: A novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
    • 1:CAS:528:DC%2BD1MXkslKqu7g%3D
    • Komoroski, B., N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister. 2009. Dapagliflozin: A novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics 85: 513-519.
    • (2009) Clinical Pharmacology and Therapeutics , vol.85 , pp. 513-519
    • Komoroski, B.1    Vachharajani, N.2    Feng, Y.3    Li, L.4    Kornhauser, D.5    Pfister, M.6
  • 32
    • 84902240389 scopus 로고    scopus 로고
    • Luseogliflozin: First global approval
    • Markham, A., and S. Elkinson. 2014. Luseogliflozin: First global approval. Drugs 74: 945-950.
    • (2014) Drugs , vol.74 , pp. 945-950
    • Markham, A.1    Elkinson, S.2
  • 33
    • 64749099761 scopus 로고    scopus 로고
    • Glucose control by the kidney: An emerging target in diabetes
    • 1:CAS:528:DC%2BD1MXlvFOjs7o%3D
    • Marsenic, O. 2009. Glucose control by the kidney: An emerging target in diabetes. American Journal of Kidney Disease 53: 875-883.
    • (2009) American Journal of Kidney Disease , vol.53 , pp. 875-883
    • Marsenic, O.1
  • 34
    • 0036737543 scopus 로고    scopus 로고
    • Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals
    • 1:CAS:528:DC%2BD38XntVShsrk%3D
    • Matsuda, M., R.A. Defronzo, L. Glass, A. Consoil, M. Giordano, P. Bressler, and S. Delprato. 2002. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51: 1111-1119.
    • (2002) Metabolism , vol.51 , pp. 1111-1119
    • Matsuda, M.1    Defronzo, R.A.2    Glass, L.3    Consoil, A.4    Giordano, M.5    Bressler, P.6    Delprato, S.7
  • 37
    • 67349224047 scopus 로고    scopus 로고
    • Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene
    • 1:CAS:528:DC%2BD1MXms1yhsrY%3D
    • Mulder, H., C. Nagorny, V. Lyssenko, and L. Groop. 2009. Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene. Diabetologia 52: 1240-1249.
    • (2009) Diabetologia , vol.52 , pp. 1240-1249
    • Mulder, H.1    Nagorny, C.2    Lyssenko, V.3    Groop, L.4
  • 39
    • 77949287535 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus
    • 1:CAS:528:DC%2BC3cXls1Sltbw%3D
    • Neumiller, J.J., J.R. White, and R.K. Campbell. 2010. Sodium-glucose co-transporter inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70: 377-385.
    • (2010) Drugs , vol.70 , pp. 377-385
    • Neumiller, J.J.1    White, J.R.2    Campbell, R.K.3
  • 41
    • 84900458799 scopus 로고    scopus 로고
    • Ipragliflozin: First global approval
    • 1:CAS:528:DC%2BC2cXmsV2nsbw%3D
    • Poole, R.M., and R.T. Dungo. 2014. Ipragliflozin: First global approval. Drugs 74: 611-617.
    • (2014) Drugs , vol.74 , pp. 611-617
    • Poole, R.M.1    Dungo, R.T.2
  • 42
    • 33644688031 scopus 로고    scopus 로고
    • Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
    • 1:CAS:528:DC%2BD2MXht12gs7fK
    • Rahmoune, H., P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown. 2005. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-3434.
    • (2005) Diabetes , vol.54 , pp. 3427-3434
    • Rahmoune, H.1    Thompson, P.W.2    Ward, J.M.3    Smith, C.D.4    Hong, G.5    Brown, J.6
  • 43
    • 0024160877 scopus 로고
    • Role of insulin resistance in human disease
    • 1:STN:280:DyaL1M%2Flt12msQ%3D%3D
    • Reaven, G.M. 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
    • (1988) Diabetes , vol.37 , pp. 1595-1607
    • Reaven, G.M.1
  • 44
    • 79956331954 scopus 로고    scopus 로고
    • Canagliflozin: A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
    • 1:CAS:528:DC%2BC3MXoslaju7o%3D
    • Sha, S., D. Devineni, A. Ghosh, D. Polidori, S. Chien, D. Wexler, K. Shalayda, K. Demarest, and P. Rothenberg. 2011. Canagliflozin: A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes, Obesity & Metabolism 13: 669-672.
    • (2011) Diabetes, Obesity & Metabolism , vol.13 , pp. 669-672
    • Sha, S.1    Devineni, D.2    Ghosh, A.3    Polidori, D.4    Chien, S.5    Wexler, D.6    Shalayda, K.7    Demarest, K.8    Rothenberg, P.9
  • 45
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlöf, K., W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel, and G. Meininger. 2013. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism 15: 372-382.
    • (2013) Diabetes, Obesity & Metabolism , vol.15 , pp. 372-382
    • Stenlöf, K.1    Cefalu, W.T.2    Kim, K.A.3    Alba, M.4    Usiskin, K.5    Tong, C.6    Canovatchel, W.7    Meininger, G.8
  • 46
    • 17044386953 scopus 로고    scopus 로고
    • Type 2 diabetes: Principles of pathogenesis and therapy
    • 1:CAS:528:DC%2BD2MXjtF2iu7g%3D
    • Stumvoll, M., B.J. Goldstein, and T.W. van Haeften. 2005. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 365: 1333-1346.
    • (2005) Lancet , vol.365 , pp. 1333-1346
    • Stumvoll, M.1    Goldstein, B.J.2    Van Haeften, T.W.3
  • 47
    • 0030018911 scopus 로고    scopus 로고
    • Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives based on a new concept
    • 1:CAS:528:DyaK28XjvVKlurw%3D
    • Tsujihara, K., M. Hongu, K. Saito, M. Inamasu, K. Arakawa, A. Oku, and M. Matsumoto. 1996. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4-dehydroxyphlorizin derivatives based on a new concept. Chemical & Pharmaceutical Bulletin (Tokyo) 44: 1174-1180.
    • (1996) Chemical & Pharmaceutical Bulletin (Tokyo) , vol.44 , pp. 1174-1180
    • Tsujihara, K.1    Hongu, M.2    Saito, K.3    Inamasu, M.4    Arakawa, K.5    Oku, A.6    Matsumoto, M.7
  • 48
    • 1242317693 scopus 로고    scopus 로고
    • The SLC2 family of facilitated hexose and polyol transporters
    • 1:CAS:528:DC%2BD2cXhtVygsLk%3D
    • Uldry, M., and B. Thorens. 2004. The SLC2 family of facilitated hexose and polyol transporters. Pflügers Archiv 447: 480-489.
    • (2004) Pflügers Archiv , vol.447 , pp. 480-489
    • Uldry, M.1    Thorens, B.2
  • 49
    • 69549095914 scopus 로고    scopus 로고
    • A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment
    • 1:CAS:528:DC%2BD1MXht1agtr3N 2732143
    • Wilding, J.P., P. Norwood, C. T'joen, A. Bastien, J.F. List, and F.T. Fiedorek. 2009. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656-1662.
    • (2009) Diabetes Care , vol.32 , pp. 1656-1662
    • Wilding, J.P.1    Norwood, P.2    T'Joen, C.3    Bastien, A.4    List, J.F.5    Fiedorek, F.T.6
  • 51
    • 78651349221 scopus 로고    scopus 로고
    • Biology of human sodium glucose transporters
    • 1:CAS:528:DC%2BC3MXns1Cms7g%3D
    • Wright, E.M., D.D. Loo, and B.A. Hirayama. 2011. Biology of human sodium glucose transporters. Physiological Reviews 91: 733-794.
    • (2011) Physiological Reviews , vol.91 , pp. 733-794
    • Wright, E.M.1    Loo, D.D.2    Hirayama, B.A.3
  • 52
    • 70549102064 scopus 로고    scopus 로고
    • Protective effects of fermented ginseng on streptozotocin-induced pancreatic β-cell damage through inhibition of NF-κB
    • 19956901
    • Yuan, H.D., and S.H. Chung. 2010. Protective effects of fermented ginseng on streptozotocin-induced pancreatic β-cell damage through inhibition of NF-κB. International Journal of Molecular Medicine 25: 53-58.
    • (2010) International Journal of Molecular Medicine , vol.25 , pp. 53-58
    • Yuan, H.D.1    Chung, S.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.